Protagonist Therapeutics Inc
PTGX56.070USD
+1.080+1.96%
Fechamento 08/15, 16:00（ET）Cotações atrasadas em 15 min
3.47BValor de mercado
10.01P/L TTM
Mais detalhes de Protagonist Therapeutics Inc Empresa
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Informações da empresa
Código da empresaPTGX
Nome da EmpresaProtagonist Therapeutics Inc
Data de listagemAug 11, 2016
CEODr. Dinesh V. Patel, Ph.D.
Número de funcionários126
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 11
Endereço7707 Gateway Blvd Ste 140
CidadeNEWARK
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94560-1160
Telefone15104740170
Sitehttps://www.protagonist-inc.com/
Código da empresaPTGX
Data de listagemAug 11, 2016
CEODr. Dinesh V. Patel, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
314.22K
-12.00%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-100.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
314.22K
-12.00%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
13.60%
Farallon Capital Management, L.L.C.
9.92%
RTW Investments L.P.
9.25%
The Vanguard Group, Inc.
6.99%
Deep Track Capital LP
5.22%
Outro
55.03%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
13.60%
Farallon Capital Management, L.L.C.
9.92%
RTW Investments L.P.
9.25%
The Vanguard Group, Inc.
6.99%
Deep Track Capital LP
5.22%
Outro
55.03%
Tipos de investidores
Investidores
Proporção
Investment Advisor
39.47%
Hedge Fund
29.91%
Investment Advisor/Hedge Fund
28.71%
Research Firm
4.59%
Venture Capital
4.14%
Private Equity
1.85%
Pension Fund
1.11%
Individual Investor
1.03%
Bank and Trust
0.37%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
533
68.00M
109.30%
-9.94M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
2023Q2
411
59.30M
103.68%
-17.88M
2023Q1
397
55.80M
108.46%
-12.55M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
8.60M
13.87%
-162.95K
-1.86%
Mar 31, 2025
Farallon Capital Management, L.L.C.
6.11M
9.85%
+177.00K
+2.98%
Mar 31, 2025
RTW Investments L.P.
5.72M
9.23%
+220.87K
+4.02%
Mar 31, 2025
The Vanguard Group, Inc.
4.27M
6.88%
+57.18K
+1.36%
Mar 31, 2025
Deep Track Capital LP
3.25M
5.24%
+250.00K
+8.33%
Apr 03, 2025
BVF Partners L.P.
3.21M
5.18%
+636.03K
+24.70%
Jun 09, 2025
State Street Global Advisors (US)
2.71M
4.37%
-624.44K
-18.75%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.95%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.42M
2.3%
+46.50K
+3.38%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qua, 6 de ago
Atualizado em: qua, 6 de ago
Nome
Proporção
Invesco Biotechnology & Genome ETF
3.16%
Invesco Dorsey Wright Healthcare Momentum ETF
2.45%
ALPS Medical Breakthroughs ETF
2.31%
Invesco S&P SmallCap Health Care ETF
2.25%
Invesco S&P SmallCap 600 Pure Growth ETF
2.08%
ETC 6 Meridian Small Cap Equity ETF
1.57%
SPDR S&P Biotech ETF
1.09%
Cambria Value and Momentum ETF
0.94%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Direxion Daily S&P Biotech Bull 3X Shares
0.7%
Ver Mais
Invesco Biotechnology & Genome ETF
Proporção3.16%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção2.45%
ALPS Medical Breakthroughs ETF
Proporção2.31%
Invesco S&P SmallCap Health Care ETF
Proporção2.25%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporção2.08%
ETC 6 Meridian Small Cap Equity ETF
Proporção1.57%
SPDR S&P Biotech ETF
Proporção1.09%
Cambria Value and Momentum ETF
Proporção0.94%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.88%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.7%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
